Compare F.N.B. Corporation Common Stock (FNB) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F.N.B. Corporation Common Stock vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? F.N.B. Corporation Common Stock trades at $16.96 (market cap $6.03B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: F.N.B. Corporation Common Stock is far larger — about 6.2× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and F.N.B. Corporation Common Stock pays a 3.07% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold F.N.B. Corporation Common Stock for 0 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FNB | MRVI | |
|---|---|---|
Market Cap | $6.03B | $977.37M |
Volume | 7,117,178 | 2,742,564 |
Sector | Financials | Health |
52-Week High | $19.49 | $9.00 |
52-Week Low | $14.65 | $2.83 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $10.52B | $1.08B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNB trades at $17.05, down 0.76% on the day, with a neutral technical signal. The stock shows solid fundamentals with a P/E of 10.15 and P/B of 0.89, indicating potential undervaluation. Recent earnings have been mixed, with Q2 2026 beating estimates but Q1 missing. Revenue remains stable at $1.77 billion for 2025, with a strong net income margin of 33.04%. Analyst sentiment is positive, with 13 buy ratings and a consensus price target of $20.80.
The outlook for FNB is cautiously optimistic, supported by strong profitability and a favorable analyst consensus. Key opportunities include potential upside to the price target and consistent dividend payments. Risks involve earnings volatility, as seen in recent quarters, and competitive pressures in the banking sector. Investors should weigh the attractive valuation against execution risks and market conditions.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About F.N.B. Corporation Common Stock
F.N.B. Corporation is a diversified financial services holding company headquartered in Pittsburgh, Pennsylvania, operating through its lead subsidiary, First National Bank of Pennsylvania. It provides commercial banking, consumer banking, wealth management, and insurance through more than 350 banking offices across seven states and Washington, D.C.
Read more on FNB →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
